TCL Archive Abraxane Combination Improves Survival In Treatment-Naïve Metastatic Disease February 22, 2013
TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
